Related Experiment Video
Updated: Dec 25, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease
Christopher Gromisch1, Motaz Qadan2, Mariana Albuquerque Machado1
1Departments of Pharmacology and Experimental Therapeutics, Biomedical Engineering, and Chemistry, Boston University, Boston, Massachusetts.
Abstract:
This review highlights current treatments, limitations, and pitfalls in the management of pancreatic cancer and discusses current research in novel targets and drug development to overcome these clinical challenges. We begin with a review of the clinical landscape of pancreatic cancer, including genetic and environmental risk factors, as well as limitations in disease diagnosis and prevention. We next discuss current treatment paradigms for pancreatic cancer and the shortcomings of targeted therapy in this disease. Targeting major driver mutations in pancreatic cancer, such as dysregulation in the KRAS and TGFβ signaling pathways, have failed to improve survival outcomes compared with nontargeted chemotherapy; thus, we describe new advances in therapy such as Ras-binding pocket inhibitors. We then review next-generation approaches in nanomedicine and drug delivery, focusing on preclinical advancements in novel optical probes, antibodies, small-molecule agents, and nucleic acids to improve surgical outcomes in resectable disease, augment current therapies, expand druggable targets, and minimize morbidity. We conclude by summarizing progress in current research, identifying areas for future exploration in drug development and nanotechnology, and discussing future prospects for management of this disease.
Insights
Pancreatic cancer treatments face limitations. Novel drug development, nanomedicine, and targeted therapies like Ras-binding pocket inhibitors offer new hope for improved patient outcomes and overcoming clinical challenges.
Area of Science:
- Oncology
- Drug Development
- Nanomedicine
Background:
- Pancreatic cancer presents diagnostic and preventative challenges.
- Current treatments and targeted therapies show significant limitations in improving survival outcomes.
- Major driver mutations (e.g., KRAS, TGFβ) have not yielded expected survival benefits.
Purpose of the Study:
- To review current pancreatic cancer management, identify limitations, and explore novel therapeutic strategies.
- To discuss advancements in drug development, nanomedicine, and targeted therapies.
- To highlight future research directions for improved pancreatic cancer treatment.
Main Methods:
- Review of existing literature on pancreatic cancer treatments and targeted therapies.
- Analysis of preclinical advancements in nanomedicine and drug delivery systems.
- Exploration of novel therapeutic targets and agents, including Ras-binding pocket inhibitors.
Main Results:
- Targeting KRAS and TGFβ signaling pathways has not improved survival compared to chemotherapy.
- New therapeutic approaches, including Ras-binding pocket inhibitors, show promise.
- Nanomedicine and advanced drug delivery systems are being developed to enhance treatment efficacy and minimize morbidity.
Conclusions:
- Overcoming pancreatic cancer challenges requires novel therapeutic targets and drug development.
- Nanotechnology and advanced drug delivery hold potential for improving surgical outcomes and augmenting current therapies.
- Future research should focus on expanding druggable targets and refining nanomedicine approaches for better patient management.
